In recent decades, substantial data from ICH have consistently demonstrated that CX3CL1/CX3CR1 signaling can achieve some neuroprotective effects in the pathology of ICH, including contributing to the absorption of hematoma size and reducing cellular death. This evidence concerns the gene CX3CL1 and hematoma.